Insider Selling: Privia Health Group (NASDAQ:PRVA) Director Sells 13,647 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 13,647 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.01, for a total transaction of $341,311.47. Following the completion of the transaction, the director owned 68,188 shares of the company’s stock, valued at $1,705,381.88. This trade represents a 16.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Privia Health Group Stock Down 2.2%

NASDAQ:PRVA traded down $0.53 during trading hours on Tuesday, hitting $23.81. 814,953 shares of the stock were exchanged, compared to its average volume of 833,471. The company’s 50 day moving average is $24.45 and its two-hundred day moving average is $22.80. The company has a market capitalization of $2.93 billion, a P/E ratio of 183.17, a price-to-earnings-growth ratio of 4.30 and a beta of 0.83. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Tuesday, June 7th. The company reported $0.10 EPS for the quarter. The firm had revenue of $213.61 million during the quarter. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%. On average, equities research analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on PRVA. Truist Financial reissued a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Privia Health Group in a research note on Monday, November 10th. JMP Securities raised their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the company a “market outperform” rating in a research note on Friday, August 29th. Evercore ISI upped their target price on shares of Privia Health Group from $28.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Citizens Jmp increased their price target on Privia Health Group from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Finally, JPMorgan Chase & Co. raised their price target on Privia Health Group from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $30.42.

Institutional Investors Weigh In On Privia Health Group

Several hedge funds have recently bought and sold shares of the company. Advantage Alpha Capital Partners LP acquired a new stake in Privia Health Group during the 2nd quarter worth approximately $3,941,000. Hsbc Holdings PLC increased its position in shares of Privia Health Group by 69.2% during the second quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock worth $2,549,000 after acquiring an additional 46,526 shares in the last quarter. Strs Ohio bought a new stake in shares of Privia Health Group during the first quarter worth $849,000. Edgestream Partners L.P. acquired a new stake in shares of Privia Health Group during the second quarter worth $2,209,000. Finally, State of Alaska Department of Revenue lifted its position in Privia Health Group by 9.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 62,406 shares of the company’s stock valued at $1,435,000 after acquiring an additional 5,223 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.